Alumis (ALMS) has had the highest return since October 2, 2025 by a mid-cap US stock, returning 500.7%.
| ASSET | % RETURN |
|---|---|
Alumis (ALMS) | 500.74% |
Praxis Precision Medicines (PRAX) | 488.24% |
Hycroft Mining (HYMC) | 465.91% |
Erasca (ERAS) | 369.2% |
Terns Pharmaceuticals (TERN) | 343.59% |
Structure Therapeutics Inc American Depositary Shares (GPCR) | 239.54% |
Vicor (VICR) | 216.48% |
Banco Macro SA B ADR (BMA) | 153.52% |
BBVA Banco Frances SA ADR (BBAR) | 151.66% |
Cogent Biosciences (COGT) | 151.47% |
Immunitybio (IBRX) | 150% |
Celcuity LLC (CELC) | 141.76% |
PACS (PACS) | 139.43% |
Olema Pharmaceuticals (OLMA) | 132.55% |
Belite Bio Inc ADR (BLTE) | 129.99% |
Cidara Therapeutics (CDTX) | 129.79% |
Fluence Energy (FLNC) | 125.83% |
Immunome (IMNM) | 117.49% |
Central Puerto (CEPU) | 108.06% |
Grupo Financiero Galicia SA ADR (GGAL) | 107.72% |
Liberty Oilfield Services (LBRT) | 97.34% |
Arrowhead Pharmaceuticals (ARWR) | 95.57% |
Spyre Therapeutics (SYRE) | 93.7% |
Telecom Argentina SA ADR (TEO) | 91.25% |
Liquidia Technologies (LQDA) | 90.52% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
